Table 1.
List of probes highlighted in this manuscript and their preclinical or clinical status
| Name | Pre-clinical/clinical trials | Notes |
|---|---|---|
| Tumor Paint (BLZ-100) | Phase 1 clinical trials for adult skin cancer (completed March 2015), sarcoma, pediatric tumors of the central nervous system (CNS), glioma, and other solid tumors | NCT02097875, NCT02464332, NCT02462629, NCT02234297, NCT02496065 |
| CLR1501 and CLR1502 | Pre-clinical animal models | (Swanson, et al., 2015) |
| OTL38 | Phase II clinical trial for FRα-positive ovarian cancer | NCT02317705 |
| cRGD-ZW800-1 | Pre-clinical animal models | (Choi, et al., 2013) |
| YC-27 | Pre-clinical animal models | (Neuman, et al., 2015) |
| PSMA-1-IR800 | Pre-clinical animal models | (Wang, et al., 2014) |
| Fluorocoxib A | Pre-clinical animal models | (Ra, et al., 2015; Uddin, et al., 2010) |
| BMV109 | Pre-clinical animal models | (Segal, et al., 2015; Verdoes, et al., 2013) |
| LUM105 | Phase I clinical trials for sarcomas, soft tissue sarcomas and breast cancer; feasibility clinical trials for breast cancer, GI cancers of the colon, esophagus and pancreas | NCT01626066, NCT02438358, NCT02584244 |
| C-PGC probe | Pre-clinical animal models | (Weissleder, et al., 1999) |
| MMP-2-sensitive NIRF probe | Pre-clinical animal models | (Bremer, et al., 2001) |
| Z-Phe-Arg-HMRG | Pre-clinical animal models | (Fujii, et al., 2014) |
| Lipidated probe 3 | Pre-clinical animal models | (Hu, et al., 2014) |
| 6QCNIR | Pre-clinical animal models | (Ofori, et al., 2015) |
| RACPP AVB-620 | Phase I clinical trial for breast cancer | NCT02391194 |
| C-SNAF | Pre-clinical animal models | (Ye, et al., 2014) |